RGMB antibody (AA 47-404)

Catalog No. ABIN7875162

The Rabbit Polyclonal anti-RGMB antibody is suitable to detect RGMB in samples from Human and Mouse. It has been validated for WB, ELISA and FACS.

Quick Overview for RGMB antibody (AA 47-404) (ABIN7875162)

Target: RGMB (RGM Domain Family, Member B (RGMB))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This RGMB antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Product Details anti-RGMB Antibody

Binding Specificity: AA 47-404

Purpose: RGMB Antibody / Repulsive Guidance Molecule B

Purification: Affinity purified

Immunogen: Recombinant human protein (amino acids D47-R404) was used as the immunogen for the RGMB antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the RGMB antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the RGMB antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for RGMB

Target: RGMB (RGM Domain Family, Member B (RGMB))

Alternative Name: RGMB

Background: Repulsive guidance molecule B (RGMb), also known as DRAGON (DRG11-responsive axonal guidance and outgrowth of neurite), is a bone morphogenetic protein (BMP) co-receptor of the repulsive guidance molecule family. In humans this protein is encoded by the RGMB gene. RGMB is a glycosylphosphatidylinositol (GPI)-anchored member of the repulsive guidance molecule family (see also RGMA and RGMC) and contributes to the patterning of the developing nervous system. There is a potential association between RGMs and cancer bone metastasis, as RGMs coordinate bone morphogenetic protein (BMP) signaling. RGMB may act as a negative regulator in vitro in breast cancer and prostate cancer through BMP signalling. Furthermore, aberrant expression of RGMs was indicated in breast cancer. The perturbed expression was associated with disease progression and poor prognosis.

UniProt: Q6NW40